146 related articles for article (PubMed ID: 9160344)
1. The MS Impairment Scale: a pragmatic approach to the assessment of impairment in patients with multiple sclerosis.
Ravnborg M; Grønbech-Jensen M; Jønsson A
Mult Scler; 1997 Feb; 3(1):31-42. PubMed ID: 9160344
[TBL] [Abstract][Full Text] [Related]
2. Responsiveness of the Multiple Sclerosis Impairment Scale in comparison with the Expanded Disability Status Scale.
Ravnborg M; Blinkenberg M; Sellebjerg F; Ballegaard M; Larsen SH; Sørensen PS
Mult Scler; 2005 Feb; 11(1):81-4. PubMed ID: 15732271
[TBL] [Abstract][Full Text] [Related]
3. Multiple Sclerosis Impact Scale (MSIS-29): relation to established measures of impairment and disability.
Hoogervorst EL; Zwemmer JN; Jelles B; Polman CH; Uitdehaag BM
Mult Scler; 2004 Oct; 10(5):569-74. PubMed ID: 15471375
[TBL] [Abstract][Full Text] [Related]
4. The patient knows best: significant change in the physical component of the Multiple Sclerosis Impact Scale (MSIS-29 physical).
Costelloe L; O'Rourke K; Kearney H; McGuigan C; Gribbin L; Duggan M; Daly L; Tubridy N; Hutchinson M
J Neurol Neurosurg Psychiatry; 2007 Aug; 78(8):841-4. PubMed ID: 17332049
[TBL] [Abstract][Full Text] [Related]
5. The multiple sclerosis impact scale (MSIS-29) is a reliable and sensitive measure.
McGuigan C; Hutchinson M
J Neurol Neurosurg Psychiatry; 2004 Feb; 75(2):266-9. PubMed ID: 14742602
[TBL] [Abstract][Full Text] [Related]
6. Tried and tested: the psychometric properties of the multiple sclerosis impact scale (MSIS-29) in a population-based study.
Gray O; McDonnell G; Hawkins S
Mult Scler; 2009 Jan; 15(1):75-80. PubMed ID: 18829636
[TBL] [Abstract][Full Text] [Related]
7. Multiple sclerosis impairment scale and brain MRI in secondary progressive multiple sclerosis.
Theodorsdottir A; Larsen PV; Nielsen HH; Illes Z; Ravnborg MH
Acta Neurol Scand; 2022 Mar; 145(3):332-347. PubMed ID: 34799851
[TBL] [Abstract][Full Text] [Related]
8. Walking function in clinical monitoring of multiple sclerosis by telemedicine.
Sola-Valls N; Blanco Y; Sepúlveda M; Llufriu S; Martínez-Lapiscina EH; La Puma D; Graus F; Villoslada P; Saiz A
J Neurol; 2015 Jul; 262(7):1706-13. PubMed ID: 25957639
[TBL] [Abstract][Full Text] [Related]
9. The psychometric properties of clinical rating scales used in multiple sclerosis.
Sharrack B; Hughes RA; Soudain S; Dunn G
Brain; 1999 Jan; 122 ( Pt 1)():141-59. PubMed ID: 10050902
[TBL] [Abstract][Full Text] [Related]
10. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the Kurtkze expanded disability status scale and the functional independence measure: measures of multiple sclerosis-related disability.
Rabadi MH; Vincent AS
Disabil Rehabil; 2013; 35(22):1877-84. PubMed ID: 23600712
[TBL] [Abstract][Full Text] [Related]
12. Comparison of patient-reported outcome measures in multiple sclerosis.
Schäffler N; Schönberg P; Stephan J; Stellmann JP; Gold SM; Heesen C
Acta Neurol Scand; 2013 Aug; 128(2):114-21. PubMed ID: 23398571
[TBL] [Abstract][Full Text] [Related]
13. Observer disagreement in rating neurologic impairment in multiple sclerosis: facts and consequences.
Verdier-Taillefer MH; Zuber M; Lyon-Caen O; Clanet M; Gout O; Louis C; Alpérovitch A
Eur Neurol; 1991; 31(2):117-9. PubMed ID: 2044616
[TBL] [Abstract][Full Text] [Related]
14. Disability weight for each level of the Expanded Disability Status Scale in multiple sclerosis.
Cho JY; Hong KS; Kim HJ; Kim SH; Min JH; Kim NH; Ahn SW; Park MS; An JY; Kim BJ; Kim W
Mult Scler; 2014 Aug; 20(9):1217-23. PubMed ID: 24399825
[TBL] [Abstract][Full Text] [Related]
15. Cognitive processing speed has minimal influence on the construct validity of Multiple Sclerosis Walking Scale-12 scores.
Motl RW; Cadavid D; Sandroff BM; Pilutti LA; Pula JH; Benedict RH
J Neurol Sci; 2013 Dec; 335(1-2):169-73. PubMed ID: 24104065
[TBL] [Abstract][Full Text] [Related]
16. [Validation of selected aspects of psychometry of the Polish version of the Multiple Sclerosis Impact Scale 29 (MSIS-29)].
Jamroz-Wiśniewska A; Papuć E; Bartosik-Psujek H; Belniak E; Mitosek-Szewczyk K; Stelmasiak Z
Neurol Neurochir Pol; 2007; 41(3):215-22. PubMed ID: 17629814
[TBL] [Abstract][Full Text] [Related]
17. The measurement of ambulatory impairment in multiple sclerosis.
Schwid SR; Goodman AD; Mattson DH; Mihai C; Donohoe KM; Petrie MD; Scheid EA; Dudman JT; McDermott MP
Neurology; 1997 Nov; 49(5):1419-24. PubMed ID: 9371932
[TBL] [Abstract][Full Text] [Related]
18. Quantifying the impact of upper limb tremor on the quality of life of people with multiple sclerosis: a comparison between the QUEST and MSIS-29 scales.
Tang CC; Soh SE; Boonstra F; Noffs G; Kolbe SC; Butzkueven H; Evans A; Van der Walt A
Mult Scler Relat Disord; 2022 Feb; 58():103495. PubMed ID: 35085981
[TBL] [Abstract][Full Text] [Related]
19. MS-CANE: a computer-aided instrument for neurological evaluation of patients with multiple sclerosis: enhanced reliability of expanded disability status scale (EDSS) assessment.
Cohen YC; Hassin-Baer S; Olmer L; Barishev R; Goldhammer Y; Freedman L; Mozes B
Mult Scler; 2000 Oct; 6(5):355-61. PubMed ID: 11064447
[TBL] [Abstract][Full Text] [Related]
20. Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite.
Hobart J; Kalkers N; Barkhof F; Uitdehaag B; Polman C; Thompson A
Mult Scler; 2004 Feb; 10(1):41-6. PubMed ID: 14760951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
